News | January 20, 2026
Alto Neuroscience bags new US patent for depression drug ALTO-207
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
A total of 300 transgender individuals were screened as part of the study, with 82 identified as high-risk due to symptoms of anxiety, depression, and self-harm or suicidal tendencies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
